Table 1.
Characteristics of the ER + /HER2-cohort at time of diagnosis of primary disease
| Characteristic | All patients (113) | ESR1 mutant (34) | ESR1 WT (79) | p-values | PIK3CA mutant (36) | PIK3CA WT (77) | p-values |
|---|---|---|---|---|---|---|---|
| Median age at random assignment, years (IQR) | 57.1 (48.7, 65.1) | 57.1 (52.8, 68.1) | 56.7 (46.7, 64.6) | 0.16 | 57.9 (49.1, 63.4) | 56.7 (48.4, 65.1) | 0.61 |
| Tumor grade | |||||||
| I | 12 (10.6%) | 6 (17.6%) | 6 (7.6%) | 0.19 | 6 (16.7%) | 6 (7.8%) | 0.19 |
| II | 50 (44.2%) | 15 (44.1%) | 35 (44.3%) | 15 (41.7%) | 35 (45.4%) | ||
| III | 43(38.1%) | 10 (29.4%) | 33 (41.8%) | 13 (36.1%) | 30 (39.0%) | ||
| Unknown | 8 (7.1%) | 3 (8.8%) | 5 (6.3%) | 2 (5.5%) | 6 (7.8%) | ||
| Stage | |||||||
| 0 | 1 (0.9%) | 0 (0%) | 1 (1.3%) | 0.022 | 0 (0%) | 1 (1.3%) | 0.48 |
| I | 23 (20.4%) | 13 (38.2%) | 10 (12.7%) | 10 (27.8%) | 13 (16.9%) | ||
| II | 52 (46.0%) | 14 (41.2%) | 38 (48.1%) | 15 (41.7%) | 37 (48.0%) | ||
| III | 10 (8.8%) | 4 (11.8%) | 6 (7.6%) | 5 (13.9%) | 5 (6.5%) | ||
| IV | 21 (18.6%) | 3 (8.8%) | 18 (22.8%) | 6 (16.7%) | 15 (19.5%) | ||
| Unknown | 6 (5.3%) | 0 (0%) | 6 (7.6%) | 0 (0%) | 6 (7.8%) | ||
| PR status-primary | |||||||
| Positive | 92 (81.4%) | 27 (79.4%) | 65 (82.3%) | 0.77 | 30 (83.3%) | 62 (80.5%) | 0.38 |
| Negative | 15 (13.3%) | 5 (14.7%) | 10 (12.7%) | 3 (8.3%) | 12 (15.6%) | ||
| Unkown | 6 (5.3%) | 2 (5.9%) | 4 (5.1%) | 3 (8.3%) | 3 (3.9%) | ||